Retatrutide – Comprehensive Research Overview (2026)
Retatrutide is a novel triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Developed by Eli Lilly, it represents the next frontier in metabolic pharmacology beyond dual agonists like tirzepatide. By adding glucagon receptor agonism to the GLP-1/GIP combination, retatrutide drives additional energy expenditure and hepatic fat reduction, producing some of the most dramatic weight loss results seen in clinical trials to date.
→ View Retatrutide (for laboratory research use only)
Mechanism of Action
- GLP-1 agonism: Appetite suppression, slowed gastric emptying, improved insulin secretion.
- GIP agonism: Enhanced insulin response, adipose tissue remodeling, synergistic weight loss.
- Glucagon agonism: Increased energy expenditure, hepatic fat mobilization, thermogenesis.
Clinical Evidence and Research Findings
Phase 2 trials demonstrated weight loss of up to 24.2% over 48 weeks at the highest dose — the largest weight reduction reported for any pharmacological agent in a Phase 2 trial as of 2024. Significant reductions in liver fat, triglycerides, and metabolic markers were also observed. Phase 3 trials (TRIUMPH program) are ongoing.
→ Interested in researching Retatrutide? View Product Options
Benefits (Research & Clinical Observations)
- Exceptional weight loss (≥20% in Phase 2)
- Significant hepatic fat reduction (MASLD/NASH research)
- Improved glycemic control and lipid profiles
- Potential for cardiovascular risk reduction
Typical Dosing Protocols (Research / Clinical Trials)
- Clinical trial doses: 1–12 mg subcutaneous once weekly
- Titration over 24 weeks to minimize GI side effects
Safety Profile and Side Effects
Common side effects: Nausea, vomiting, diarrhea, decreased appetite, injection-site reactions. Generally manageable with slow titration. Heart rate increases observed at higher doses (glucagon effect).
Monitoring recommended: Heart rate, GI tolerance, liver enzymes, renal function, metabolic markers.
Retatrutide vs Tirzepatide vs Semaglutide – Quick Comparison
| Aspect | Retatrutide | Tirzepatide | Semaglutide |
|---|---|---|---|
| Mechanism | GLP-1 + GIP + Glucagon | GLP-1 + GIP | GLP-1 |
| Weight Loss | ~24% (Phase 2) | ~20%+ (Phase 3) | ~15% (Phase 3) |
| FDA Status | Phase 3 (not approved) | Approved (obesity, T2D) | Approved (obesity, T2D) |
Summary
Retatrutide is the most potent weight-loss agent in late-stage clinical development, leveraging triple receptor agonism for unprecedented metabolic effects. Its Phase 2 results have set new benchmarks for pharmacological obesity treatment. As with all compounds in this library, Retatrutide is not yet an approved drug and should only be considered under qualified medical supervision.
For Laboratory Research Use View Retatrutide →
Disclaimer This overview is strictly educational and based on publicly available scientific literature and regulatory information as of April 2026. It does not constitute medical advice, endorsement, or encouragement of use. Always consult a qualified healthcare professional and comply with all applicable laws and regulations.